Pulmatrix (NASDAQ:PULM) Posts Earnings Results, Beats Estimates By $1.71 EPS

Pulmatrix (NASDAQ:PULM) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($2.00) by $1.71, FiscalAI reports.

Pulmatrix Stock Down 5.6%

Shares of NASDAQ:PULM traded down $0.09 during midday trading on Thursday, reaching $1.51. 20,613 shares of the company traded hands, compared to its average volume of 10,308. The firm’s fifty day moving average price is $1.61 and its two-hundred day moving average price is $1.76. The firm has a market capitalization of $5.51 million, a price-to-earnings ratio of -1.23 and a beta of 1.91. Pulmatrix has a 12 month low of $1.16 and a 12 month high of $5.50.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Pulmatrix from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 30th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Institutional Investors Weigh In On Pulmatrix

A hedge fund recently bought a new position in Pulmatrix stock. DRW Securities LLC bought a new position in shares of Pulmatrix, Inc. (NASDAQ:PULM) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 20,505 shares of the biotechnology company’s stock, valued at approximately $46,000. Hedge funds and other institutional investors own 11.84% of the company’s stock.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).